Pharmaceutical

Mankind Pharma has acquired the rights to the Rivotril brand from Roche for the Indian market, marking a strategic expansion into chronic and specialty therapies. Rivotril, a widely prescribed formulation of clonazepam, is used in the treatment of neurological and psychiatric conditions. The deal grants Mankind Pharma exclusive authority to manufacture, market, and distribute the product across India.

Agilisium has announced a strategic investment of Rs. 50 crore to drive artificial intelligence adoption across the pharmaceutical, biotechnology, and medical technology sectors. The initiative focuses on embedding AI capabilities within enterprise operations through a specialized workforce model known as Forward Deployment Experts (FDX). By reskilling over 1,000 professionals globally, the company aims to bridge the gap between AI potential and real-world implementation.

Zydus Lifesciences has achieved a significant regulatory milestone after securing approval in China for its innovative drug Desidustat, developed to treat renal anemia associated with chronic kidney disease (CKD). The authorization from China’s National Medical Products Administration (NMPA) allows the oral medication to be introduced in one of the world’s largest pharmaceutical markets. The drug will be commercialized through an exclusive licensing partnership with CMS International Development and Management Ltd, a subsidiary of China Medical System Holdings Ltd.